Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336798 · ClinicalTrials.gov registry record · Phase 2
Bioenergetic Effect of Pioglitazone in CLD-PH
A Phase 2 study of Pulmonary Hypertension and Pulmonary Hypertension Due to Lung Diseases, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06336798: Recruiting Phase 2 study of Pulmonary Hypertension and Pulmonary Hypertension Due to Lung Diseases, sponsored by Emory University.
NCT06336798 is a Phase 2 study of Pulmonary Hypertension and Pulmonary Hypertension Due to Lung Diseases that is actively recruiting participants, run by Emory University. The registered enrollment target is 20 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06336798, a Phase 2 study of Pulmonary Hypertension and Pulmonary Hypertension Due to Lung Diseases, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD. Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo).
Primary Outcome
Mitochondrial metabolism is measured using a research protocol employing the Agilent Seahorse extracellular flux bioanalyzer. Standard Seahorse assay protocols have been adapted for use with human platelets . Spare respiratory capacity (SRC) is calculated by (maximal respiration) - (basal respiration) during the mitochondrial stress test. The value is reported in pmol/min.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pioglitazone 30mg
- DIAGNOSTIC_TEST Labs
Study Locations (1)
Georgia
- Emory Healthcare System - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What NCT06336798 shows while recruiting
NCT06336798 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06336798 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06336798 about?
NCT06336798 is a clinical study titled "Bioenergetic Effect of Pioglitazone in CLD-PH". The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to ...
What is the current status of trial NCT06336798?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2024-12-17. Estimated completion is 2028-02.
What conditions does trial NCT06336798 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases.
What interventions are being tested in trial NCT06336798?
The interventions under investigation include: Placebo (DRUG), Pioglitazone 30mg (DRUG), Labs (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06336798?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06336798 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06336798's enrollment target sits among peer trials
20 58th of 72 higher than 11 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI